Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

ENDEAVOR Endoscopic brush cytology and single cell clinal dynamics of early easophageal adenocarcinoma for detecting cost effective surveillance strategies and prediction of cancer recurrence

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€6.7m
Total cost
€6.7m
Partners
13 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101136935

What the project is doing

In the project's own words, from its summary on CORDIS.

In many European countries the recent rise in incidence of esophageal adenocarcinoma (EAC) is without precedent. EAC is notorious for its highly aggressive biological behavior leading to invasive disease and early metastases. The only way to reduce mortality is through treatment in early stage of the cancer. EAC has a well recognized premalignant precursor lesion identified as esophageal metaplasia, or Barrett’s Esophagus (BE), which offers important opportunities for treatment in early stages of cancer which may reach 5 years survival rates up to 80%.

However, these patients need to be monitored constantly for timely intervention in case of disease recurrence or metastases. The problem is that after endoscopic treatment up to 30% of cases will develop recurring cancers or even present with metastases, which requires additional endoscopic treatments or surgery. Currently it is impossible to predict which of the treated BE patients with will have stable disease and which will recur or progress to invasive cancer.

As a consequence all treated patients need to remain in frequent endoscopic surveillance. This leads to over-treatment of a large group of BE patients and under-treatment of those with more aggressive disease. There is a low cost effectiveness of endoscopic therapies, low quality of life of patients and poor satisfaction of care providers. An accurate risk stratification method for early AEC in BE patients is therefore an unmet clinical need.

The ambition of the ENDEAVOR consortium is to implement an innovative risk stratification method, which encompasses minimally invasive cell collection supplemented by single cell genomic analysis to address this specific need. Taking into account patient characteristics, gender dimensions, an optimal model model will be tested in a randomized controlled prospective trial. Future implementation of this method will reduce health care costs, increase quality of life and satisfaction of health care providers.

This action is part of the Cancer Mission cluster of projects on Diagnostics and Treatment (diagnostics).

Topics

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator
Universitair Ziekenhuis AntwerpenEdegemBelgiumParticipant
Heinrich-Heine-Universitaet DuesseldorfDusseldorfGermanyParticipant
Universitaet LeipzigLeipzigGermanyParticipant
Region HovedstadenHillerodDenmarkParticipant
Universal Diagnostics Sociedad AnonimaSevillaSpainParticipant
Centre Hospitalier Regional Et Universitaire De LilleLilleFranceParticipant
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region StockholmStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI